Release Notes for 2026-10-25: Number of new affinity data: 3893 Number of compounds (ligands) new to BindingDB: 1677 Number of Targets new to BindingDB: 26 ChEMBL release: ChEMBL 37 New Targets: Actin-related protein 2 (ACTR2) (P61160): 1 inhibitors Angiopoietin-1 receptor (TIE2) (Q02763): 1 inhibitors Citron Rho-interacting kinase [1-499] (O14578[1-499]): 29 inhibitors Dual specificity mitogen-activated protein kinase kinase 1 (MEK-1) (Q02750): 1 inhibitors Dual specificity mitogen-activated protein kinase kinase 2 (MEK2) (P36507): 1 inhibitors High affinity nerve growth factor receptor (TrkA) (P04629): 1 inhibitors Homeodomain-interacting protein kinase 1 [156-555] (Q86Z02): 99 inhibitors Homeodomain-interacting protein kinase 2 [1-640] (Q9H2X6[1-640]): 99 inhibitors Kelch-like ECH-associated protein 1 [321-624] (Q14145): 101 inhibitors Mitogen-activated protein kinase 1 (MAPK1) (P28482): 1 inhibitors Mitogen-activated protein kinase 11 (SAPK2b) (Q15759): 1 inhibitors Mitogen-activated protein kinase 12 (SAPK3) (P53778): 1 inhibitors Mitogen-activated protein kinase 13 (SAPK4) (O15264): 1 inhibitors Mitogen-activated protein kinase 14 (SAPK2a) (Q16539): 1 inhibitors Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) (O95819): 1 inhibitors Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12) (P62942): 1 inhibitors Protein BRICK1 (Q8WUW1): 1 inhibitors RAC-alpha serine/threonine-protein kinase (PKB alpha) (P31749): 1 inhibitors Rho-associated protein kinase 2 (ROCK2) (O75116): 1 inhibitors Ribosomal protein S6 kinase alpha-5 (MSK1) (O75582): 1 inhibitors Tyrosine-protein kinase receptor TYRO3 (RSE) (Q06418): 1 inhibitors Vascular endothelial growth factor receptor 1 (P17948): 1 inhibitors cAMP-dependent protein kinase catalytic subunit alpha (PKA) (P17612): 1 inhibitors cdk2/cyclin a (P24941,P20248): 78 inhibitors cdk7/cyclinh/mnat (P51946,P50613,P51948): 81 inhibitors cdk9/cyclin k (P50750,O75909): 70 inhibitors Number of new Entries: 27 PubMed id or Patent id Title US12629358-B2 Compound used as RET kinase inhibitor and application thereof US12630497-B2 Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient US12630511-B2 Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer US12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof US12630561-B2 Tricyclic derivatives inhibitor, preparation method, and applications thereof US12630565-B2 DNA-dependent protein kinase inhibitor US12636275 Pharmaceutical use of ketoamide-based compound US12637428 Isoquinoline derivatives as SIK2 inhibitors US12637430-A1 Interleukin-17 (IL-17) inhibitors US12637440-A Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof US12637454 Heterocyclic monoacylglycerol lipase (MAGL) inhibitors US12637455 Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators US12637469 1H-pyrazole derivative and application thereof as dual target inhibitor of Syk and VEGFR2 US12643887-A Heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases US12643889A Synthesis of novel EP4 antagonist and use in cancer and inflammation US12643890 Substituted amino-pyrimidines US12643910A Substituted pyrazolo[3,4-b]pyridines as ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators US12643912 Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them US20260137669-A1 NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS US20260137698-A1 CYCLIN-DEPENDENT KINASE 7 INHIBITORS US20260137699-A1 OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF US20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF US20260138961-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION US20260138982-A1 Biaryl Acid Compounds US20260138986-A1 PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES US20260146035A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS US20260146050-A1 KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES